This Article Full Text Full Text (PDF) All Versions of this Article: 27/11/2463    most recent ATVBAHA.107.151670v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabatine, M. S. Search for Related Content PubMed PubMed Citation Articles by Sabatine, M. S. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Coronary Artery Disease

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:2463.)
© 2007 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Prognostic Utility of Lipoprotein-Associated Phospholipase A₂ for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease

Marc S. Sabatine; David A. Morrow; Michelle O’Donoghue; Kathleen A. Jablonksi; Madeline Murguia Rice; Scott Solomon; Yves Rosenberg; Michael J. Domanski; Judith Hsia for the PEACE Investigators

From the Cardiovascular Division (M.S.S., D.A.M., M.O., S.S.), Brigham and Women’s Hospital and Department of Medicine, Harvard Medical School, Boston, MA; the George Washington University (K.A.J., M.M.R., J.H.), Rockville, Md & Washington, DC; and the National Heart, Lung, and Blood Institute (Y.R., M.J.D.), Bethesda, Md.

Correspondence to Marc S. Sabatine, MD, MPH, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115. E-mail msabatine{at}partners.org

Objective— To determine the prognostic utility of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) for specific adverse cardiovascular outcomes in patients with stable coronary artery disease (CAD), independent of traditional risk factors and high-sensitivity C-reactive protein (hs-CRP).

Methods and Results— We measured Lp-PLA₂ in 3766 patients with stable CAD from the PEACE trial. Patients were followed for a median of 4.8 years for adverse cardiovascular events including death, myocardial infarction (MI), coronary revascularization, hospitalization for unstable angina (UA), and stroke. Multivariable Cox regression was used to adjust for traditional cardiovascular risk factors and to conduct multimarker analyses that included hs-CRP. After adjustment for baseline characteristics, patients in higher quartiles of Lp-PLA₂ remained at significantly greater risk for the composite of cardiovascular death, MI, coronary revascularization, UA, or stroke (P<0.001 for trend, adj HR 1.41, 95% CI 1.17 to 1.70, for patients in 4th versus 1st quartile). The association was consistent regardless of a patient’s sex, cholesterol levels, or use of lipid-lowering therapy. When analyzed together, both hs-CRP and Lp-PLA₂ were highly significant predictors of acute coronary syndromes (cardiovascular death, MI, or UA) (P for trend <0.001 for hs-CRP and 0.005 for Lp-PLA₂), whereas only Lp-PLA₂ was a significant predictor of coronary revascularization (P=0.01 for trend).

Conclusions— In stable CAD, an elevated level of Lp-PLA₂ was a significant predictor of nonfatal adverse cardiovascular outcomes independent of traditional clinical risk factors and hs-CRP. Further investigation will be needed to establish whether therapies that lower Lp-PLA₂ reduce cardiovascular risk.

In 3766 patients with stable CAD, an elevated level of Lp-PLA₂ was a significant predictor of adverse cardiovascular outcomes independent of traditional clinical risk factors. When analyzed together, both hs-CRP and Lp-PLA₂ were highly significant predictors of ACS, whereas only Lp-PLA₂ was a significant predictor of revascularization.

Key Words: coronary disease • lipoprotein-associated phospholipase A₂ • C-reactive protein

This article has been cited by other articles:

				A. A. Gardner, E. C. Reichert, M. K. Topham, and D. M. Stafforini Identification of a Domain That Mediates Association of Platelet-activating Factor Acetylhydrolase with High Density Lipoprotein J. Biol. Chem., June 20, 2008; 283(25): 17099 - 17106. [Abstract] [Full Text] [PDF]

				M. F. Walter, R. F. Jacob, R. E. Bjork, B. Jeffers, J. Buch, Y. Mizuno, R. P. Mason, and on behalf of the PREVENT Investigators Circulating Lipid Hydroperoxides Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease: The PREVENT Study J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1196 - 1202. [Abstract] [Full Text] [PDF]